Bullfrog AI Holdings, Inc. (NASDAQ:BFRG) Sees Large Decline in Short Interest

Bullfrog AI Holdings, Inc. (NASDAQ:BFRG) was the recipient of a large decline in short interest during the month of November. As of November 15th, there was short interest totalling 185,000 shares, a decline of 27.5% from the October 31st total of 255,300 shares. Based on an average daily volume of 88,900 shares, the short-interest ratio is currently 2.1 days. Approximately 3.0% of the company’s shares are short sold.

Bullfrog AI Stock Up 0.5 %

Shares of NASDAQ BFRG opened at $2.15 on Friday. Bullfrog AI has a 1 year low of $1.43 and a 1 year high of $8.35. The firm’s 50-day moving average is $2.47 and its 200-day moving average is $2.49.

Insider Buying and Selling

In related news, CEO Vininder Singh sold 14,405 shares of the firm’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $2.65, for a total value of $38,173.25. Following the transaction, the chief executive officer now owns 2,478,041 shares in the company, valued at $6,566,808.65. This trade represents a 0.58 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 31,603 shares of company stock worth $82,989 in the last quarter. Insiders own 33.90% of the company’s stock.

Hedge Funds Weigh In On Bullfrog AI

An institutional investor recently bought a new position in Bullfrog AI stock. XTX Topco Ltd purchased a new stake in Bullfrog AI Holdings, Inc. (NASDAQ:BFRG) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 18,580 shares of the company’s stock, valued at approximately $32,000. XTX Topco Ltd owned 0.24% of Bullfrog AI as of its most recent SEC filing. Institutional investors and hedge funds own 0.96% of the company’s stock.

About Bullfrog AI

Bullfrog AI Holdings, Inc, through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data.